News

The designation was based on data from 7 clinical trials over the past decade which assessed Xolair's efficacy and safety versus various food allergens such as peanut, milk, and egg.

Galafold differs from common enzyme replacement therapy in that it increases the activity of the body’s deficient enzyme.

Fish oil supplements proved no better than placebo at relieving dry eye disease.

The oral therapy was previously approved for use in children aged 6 years and older with CF and 2 copies of the F508del-CFTR mutation, the most common genetic form of the disease.

When disease activity is high and/or function impaired, consider depression a likely comorbidity that may be a result of inflammation.

The goal of the study: to identify young patients at risk before any clinical symptoms develop.

Researchers suggested that anti-oxidants such as Vitamin C and E could delay or even reduce the risk of AMD in patients with gout, as they have been proven to have a beneficial effect in patients with AMD.

Two recent studies focus on radiographic progression in ankylosing spondylitis and the risk of osteoporosis in axial spondyloarthritis.

Two newly identified factors may raise the lifetime risk of symptomatic OA that requires total hip arthroplasty.

Be vigilant for cardiovascular risk factors in patients with ankylosing spondylitis, advise Norwegian researchers.

A wish list from your patients with rheumatoid arthritis who are-or who want to become-mothers.

A bisphosphonate drug holiday linked to a 20% rise in hip fractures in older women, according to a new study. 

The rare condition affects the skin and can lead to ulceration and scarring, however, there are currently no FDA approved treatments for necrobiosis lipoidica.

A potential non-immunosuppressive treatment option for patients with diffuse cutaneous systemic sclerosis.

This is the first and only therapy indicated in the US to help prevent angioedema attacks in pediatric patients as young as 6 years old.

This study suggests a link between inflammatory arthritis and the development of serious mental health consequences.

This minimally invasive procedure provides additional options for the patient population suffering with sacral insufficiency fractures.

New data from the FUTURE 5 study show that the interleukin-17A antagonist slows the progression of joint structural damage compared to placebo.

A substantial proportion of the increased cardiovascular risk in patients with OA can be attributed to these commonly used drugs.

New classification criteria for spondyloarthritis cover a wide spectrum of patients.

Early, intensive treatment of RA has long-term benefits, including a reduction in mortality, report Dutch researchers at EULAR 2018.

Men are more likely to stay the course of TNF inhibitor therapy.

Urinary markers may predict the development of osteolysis following total hip replacement.

Insights from digital patient communities on disease-related impairments that PRO tools may miss.

Real-world health claims data demonstrate an elevated risk of cardiovascular and autoimmune diseases.

Daily upadacitinib monotherapy 15 mg/30 mg met both primary endpoints with 52%/56% of methotrexate patients achieving ACR50 at week 12 and 48%/50% achieving clinical remission at week 24.

The approval is based on phase 3 clinical data that demonstrated efficacy for difficult to treat rheumatoid arthritis.

There was a dose-response pattern of psychological distress associated with significantly increased risk for COPD, cardiovascular disease, and arthritis.

After rejecting the drug in 2017, the FDA approved the 2 mg dose of baricitinib (Olumiant) for adults with moderate to severe rheumatoid arthritis.

Brush up on the diagnosis of systemic lupus erythematosus with 5 questions based on the recent British Society for Rheumatology guidelines.